JP2020522524A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522524A5
JP2020522524A5 JP2019566881A JP2019566881A JP2020522524A5 JP 2020522524 A5 JP2020522524 A5 JP 2020522524A5 JP 2019566881 A JP2019566881 A JP 2019566881A JP 2019566881 A JP2019566881 A JP 2019566881A JP 2020522524 A5 JP2020522524 A5 JP 2020522524A5
Authority
JP
Japan
Prior art keywords
asthma
antibody
pharmaceutical composition
eosinophil
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522524A (ja
JP7295038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031518 external-priority patent/WO2018226339A1/en
Publication of JP2020522524A publication Critical patent/JP2020522524A/ja
Publication of JP2020522524A5 publication Critical patent/JP2020522524A5/ja
Priority to JP2023094740A priority Critical patent/JP2023113883A/ja
Application granted granted Critical
Publication of JP7295038B2 publication Critical patent/JP7295038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566881A 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法 Active JP7295038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094740A JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762515641P 2017-06-06 2017-06-06
US62/515,641 2017-06-06
US201862619206P 2018-01-19 2018-01-19
US62/619,206 2018-01-19
PCT/US2018/031518 WO2018226339A1 (en) 2017-06-06 2018-05-08 Biopharmaceutical compositions and methods for pediatric patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094740A Division JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020522524A JP2020522524A (ja) 2020-07-30
JP2020522524A5 true JP2020522524A5 (https=) 2021-07-26
JP7295038B2 JP7295038B2 (ja) 2023-06-20

Family

ID=64566261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566881A Active JP7295038B2 (ja) 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Country Status (7)

Country Link
US (2) US11390671B2 (https=)
EP (1) EP3634467A4 (https=)
JP (2) JP7295038B2 (https=)
CN (2) CN119632921A (https=)
BR (1) BR112019025736A2 (https=)
CA (1) CA3064859A1 (https=)
WO (1) WO2018226339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
KR20210145187A (ko) * 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
ES3057414T3 (en) * 2020-12-22 2026-03-02 Glaxosmithkline Ip Dev Ltd Interleukin 5 binding protein dosage regimen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ZA898322B (en) 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
TR200001117T2 (tr) 1997-10-22 2000-09-21 Ponikau Jens Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP4597643B2 (ja) 2004-11-24 2010-12-15 富士フイルム株式会社 電子内視鏡
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
JP5035153B2 (ja) 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients

Similar Documents

Publication Publication Date Title
Wong et al. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
JP2021523188A5 (https=)
Parisi et al. Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review
JP2013543501A5 (https=)
Corren Anti-interleukin-5 antibody therapy in asthma and allerges
JP2020522524A5 (https=)
JP2002522503A (ja) 神経系障害を処置するための方法
JP2019517473A5 (https=)
McIvor Emerging therapeutic options for the treatment of patients with symptomatic asthma
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
EP4518970B1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
JP2018529766A5 (https=)
JPWO2019222055A5 (https=)
Weinberger Treatment strategies for viral respiratory infection-induced asthma
Tello et al. Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
Lucidi et al. A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients
Passalacqua et al. Novel therapeutic interventions for allergic rhinitis
WO2024056789A1 (en) Treating hiv with cabotegravir and rilpivirine in pediatric patients
JPWO2021195530A5 (https=)
CN114569623A (zh) 己酸羟孕酮在制备治疗间质性肺炎的药物中的用途
Lazarus et al. Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association
Gul et al. Safe, Rapid-Onset, and Sustained Biological Activity of IL-1beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behçet’s Disease: Preliminary Results of a Pilot Trial
Prous Annual update 2004/2005–treatment of respiratory disorders
Howell et al. Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
JP2023521909A (ja) 呼吸器疾患の治療